Becton, Dickinson and Co. (BDX) — 分析摘要
Becton, Dickinson and Co.（BDX）的市值为42.39十亿美元，最近一年的营收同比增长了+8.2%。净利润率为7.7%。当前市盈率为37.2倍。
核心要点
- 营收同比变化+8.2%
- 净利润率7.7%
- 市盈率37.2倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，BDX的营收增长为+8.2%，市盈率为37.2倍。
Becton, Dickinson and Co. (BDX)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
流动比率为 0.94x — 流动负债超过流动资产
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
72,000
总部
FRANKLIN LAKES, NJ
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$4.20
股息收益率
2.79%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。